Related Experiment Video

Updated: May 10, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Pharmacogenomics of anti-platelet and anti-coagulation therapy

Adam S Fisch1, Christina G Perry, Sarah H Stephens

  • 1Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, and the Program in Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Adam.Fisch@som.umaryland.edu

Current Cardiology Reports
|June 26, 2013
PubMed

Insights

Genetic factors influence responses to anti-thrombotic drugs like warfarin and clopidogrel, leading to variable effectiveness. Identifying these genetic factors promises personalized anti-coagulation and anti-platelet therapies for better cardiovascular event prevention.

Area of Science:

  • Pharmacogenomics
  • Vascular Biology
  • Cardiovascular Medicine

Background:

  • Arterial thrombosis contributes significantly to myocardial infarction (MI) and stroke.
  • Current anti-thrombotic drugs (e.g., warfarin, clopidogrel) show inter-individual response variability.
  • Genetic factors are increasingly recognized as key determinants of drug efficacy and safety.

Purpose of the Study:

  • To highlight the role of genetic variations in anti-thrombotic drug response.
  • To underscore the potential for personalized anti-coagulation and anti-platelet therapies.
  • To identify new diagnostic targets and therapeutic strategies for managing vascular disease.

Main Methods:

  • Review of genetic studies on warfarin and clopidogrel response.
  • Analysis of common genetic variants impacting drug metabolism and action.
  • Exploration of pharmacogenomic data for therapeutic insights.

Main Results:

  • Common genetic variants significantly affect patient response to anti-thrombotic medications.
  • Variability in drug metabolism and target pathways is linked to genetic polymorphisms.
  • Identification of specific gene variants associated with altered drug efficacy.

Conclusions:

  • Genetic profiling can guide individualized anti-thrombotic therapy selection.
  • Personalized medicine approaches hold promise for optimizing treatment of arterial thrombosis.
  • Further research into pharmacogenomics will enhance prevention of cardiovascular events like MI and stroke.

More Related Videos

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...